NCT02045875View on ClinicalTrials.gov

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 4, 2014

Primary Completion Date

July 1, 2017

Study Completion Date

July 12, 2017

Conditions
Asthma
Interventions
DRUG

Dulera

Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.

Trial Locations (1)

15212

West Penn Allegheny Health System, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

West Penn Allegheny Health System

OTHER

lead

Asthma Management Systems

INDUSTRY

NCT02045875 - Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence | Biotech Hunter | Biotech Hunter